Evidence map›Paper›PMID 24184637›Full record

ArticleDevelopmental biology2014

Cerebellar cortical lamination and foliation require cyclin A2.

José Javier Otero, Ilona Kalaszczynska, Wojciech Michowski, Michael Wong, Patrick Edwin Gygli, Hamza Numan Gokozan, Amélie Griveau, Junko Odajima, Catherine Czeisler, Fay Patsy Catacutan and 4 more

Abstract read
In one paragraph

Article in Developmental biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

José Javier OteroThe Ohio State University College of Medicine, Department of Pathology, Division of Neuropathology, 4169 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210, USA; University of California, San Francisco Department of Pathology, Division of Neuropathology, USA. Electronic address: jose.otero@osumc.edu.
Ilona KalaszczynskaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, USA; Department of Genetics, Harvard Medical School, USA; Tissue Engineering Lab, Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Poland.
Wojciech MichowskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, USA; Department of Genetics, Harvard Medical School, USA.
Michael WongUniversity of California, San Francisco Department of Pediatrics, USA.
Patrick Edwin GygliThe Ohio State University College of Medicine, Department of Pathology, Division of Neuropathology, 4169 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210, USA.
Hamza Numan GokozanThe Ohio State University College of Medicine, Department of Pathology, Division of Neuropathology, 4169 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210, USA.
Amélie GriveauUniversity of California, San Francisco Department of Pediatrics, USA.
Junko OdajimaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, USA; Department of Genetics, Harvard Medical School, USA.
Catherine CzeislerThe Ohio State University College of Medicine, Department of Pathology, Division of Neuropathology, 4169 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210, USA.
Fay Patsy CatacutanThe Ohio State University College of Medicine, Department of Pathology, Division of Neuropathology, 4169 Graves Hall, 333 W 10th Avenue, Columbus, OH 43210, USA.
Alice MurnenUniversity of California, San Francisco Department of Pediatrics, USA.
Ulrich SchüllerNeuropathology, Ludwig-Maximilians-University, Germany.
Piotr SicinskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, USA; Department of Genetics, Harvard Medical School, USA.
David RowitchUniversity of California, San Francisco Department of Pediatrics, USA.
University of California, San Francisco · USHarvard University · USThe Ohio State University · USLudwig-Maximilians-Universität München · DE

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
OLIGODENDROCYTE LINEAGE GENE FUNCTION IN THE CNSR01NS040511 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROWITCH, DAVID H · 2000 to 2014
$6.4M
Cyclin A Function in Stem Cells and in NeoplasiaR01CA132740 · NCI · DANA-FARBER CANCER INST · PI SICINSKI, PETER · 2008 to 2017
$4.4M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA132740NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1RR024131NINDS NIH HHS R01 NS040511NINDS NIH HHS R01NS40511
6 · The paper itself

Abstract

The mammalian genome encodes two A-type cyclins, which are considered potentially redundant yet essential regulators of the cell cycle. Here, we tested requirements for cyclin A1 and cyclin A2 function in cerebellar development. Compound conditional loss of cyclin A1/A2 in neural progenitors resulted in severe cerebellar hypoplasia, decreased proliferation of cerebellar granule neuron progenitors (CGNP), and Purkinje (PC) neuron dyslamination. Deletion of cyclin A2 alone showed an identical phenotype, demonstrating that cyclin A1 does not compensate for cyclin A2 loss in neural progenitors. Cyclin A2 loss lead to increased apoptosis at early embryonic time points but not at post-natal time points. In contrast, neural progenitors of the VZ/SVZ did not undergo increased apoptosis, indicating that VZ/SVZ-derived and rhombic lip-derived progenitor cells show differential requirements to cyclin A2. Conditional knockout of cyclin A2 or the SHH proliferative target Nmyc in CGNP also resulted in PC neuron dyslamination. Although cyclin E1 has been reported to compensate for cyclin A2 function in fibroblasts and is upregulated in cyclin A2 null cerebella, cyclin E1 expression was unable to compensate for loss-of cyclin A2 function.

Indexed as

AnimalsCell ProliferationCerebral CortexCyclin A2In Situ HybridizationMiceMice, KnockoutMice, TransgenicNeural Stem CellsCyclin A2Brain malformationCell cycleCNS developmentCyclin A1Cyclin A2Cyclin E1DNA repairExternal granule layerNestin

Identifiers

PMID24184637
PMCPMC3909955
OpenAlexW2016082552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.